Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H18ClN |
| Molecular Weight | 259.774 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CC1=CC=CC=C1)NCC2=CC=CC=C2Cl
InChI
InChIKey=LRXXRIXDSAEIOR-ZDUSSCGKSA-N
InChI=1S/C16H18ClN/c1-13(11-14-7-3-2-4-8-14)18-12-15-9-5-6-10-16(15)17/h2-10,13,18H,11-12H2,1H3/t13-/m0/s1
| Molecular Formula | C16H18ClN |
| Molecular Weight | 259.774 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18500382Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9987865 | https://www.ncbi.nlm.nih.gov/pubmed/9050090
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18500382
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9987865 | https://www.ncbi.nlm.nih.gov/pubmed/9050090
Clobenzorex is a central stimulant and sympathomimetic used as an anti-obesity drug; an n-substituted amphetamine, which is metabolized to amphethamine. Its actions are like those of dexamphetamine and has been used as a drug of abuse.
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.777 ng/mL |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.429 ng/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.777 ng × h/mL |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.076 ng × h/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.002 h |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.118 h |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBENZOREX plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
210 mg 3 times / day multiple, oral Higher than recommended Dose: 210 mg, 3 times / day Route: oral Route: multiple Dose: 210 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Congestive cardiomyopathy... AEs leading to discontinuation/dose reduction: Congestive cardiomyopathy Sources: |
90 mg single, oral Highest studied dose Dose: 90 mg Route: oral Route: single Dose: 90 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Congestive cardiomyopathy | Disc. AE | 210 mg 3 times / day multiple, oral Higher than recommended Dose: 210 mg, 3 times / day Route: oral Route: multiple Dose: 210 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Benfluorex and unexplained valvular heart disease: a case-control study. | 2010-04-12 |
|
| Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. | 2010-03 |
|
| Role of substance P on histamine H(3) antagonist-induced scratching behavior in mice. | 2006-04 |
|
| Amphetamine-like stimulant cessation in an abusing patient treated with bupropion. | 2004-01 |
|
| Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. | 2002-05 |
|
| Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. | 2002-04 |
|
| Amphetamine, clobenzorex, and 4-hydroxyclobenzorex levels following multidose administration of clobenzorex. | 2001-04 |
|
| Clobenzorex: evidence for amphetamine-like behavioral actions. | 1997-02 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:16:20 GMT 2025
by
admin
on
Mon Mar 31 18:16:20 GMT 2025
|
| Record UNII |
4A5352XI2A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA08AA08
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
||
|
NCI_THESAURUS |
C29728
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
||
|
WHO-ATC |
A08AA08
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
236-434-4
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
CLOBENZOREX
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
684
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
100000084281
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
C77327
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
DB13561
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
SUB06676MIG
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
4A5352XI2A
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL1213251
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
21244
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | RxNorm | ||
|
735998
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
13364-32-4
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
m3627
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID7048409
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
2363
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY | |||
|
C000490
Created by
admin on Mon Mar 31 18:16:20 GMT 2025 , Edited by admin on Mon Mar 31 18:16:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |